

Executive Branch Personnel

Public Financial Disclosure Report:

Periodic Transaction Report (OGE Form 278-T)

Filer's Information

Fink, Dorothy A

Deputy Assistant Secretary for Women's Health, Department of Health & Human Services

Electronic Signature - I certify that the statements I have made in this form are true, complete and correct to the best of my knowledge.

/s/ Fink, Dorothy A [electronically signed on 04/06/2020 by Fink, Dorothy A in Integrity.gov]

Agency Ethics Official's Opinion - On the basis of information contained in this report, I conclude that the filer is in compliance with applicable laws and regulations (subject to any comments below).

/s/ Reed, Paul L, Certifying Official [electronically signed on 10/02/2020 by Reed, Paul L in Integrity.gov]

Other review conducted by

/s/ McClure, Chester, Ethics Official [electronically signed on 08/25/2020 by McClure, Chester in Integrity.gov]

U.S. Office of Government Ethics Certification

Data Revised 08/25/2020

Comments of Reviewing Officials (public annotations):

PART	#	REFERENCE	COMMENT
N/A	N/A	General	(04/06/2020, McClure, Chester): Preliminary Review 4/6/2020
N/A	N/A	General	(08/25/2020, McClure, Chester): Filer confirmed that spousal purchases of stock in healthcare, pharmaceutical, medical device, health insurance, or health-related technology sectors on this report were less than \$3,000 per stock and the maximum value held at any time was less than \$8,500 for any stock. After subsequent sales as indicated on this report, filer confirmed as of June 2020, spouse held only the following stock: Collegium Pharmaceutical, Intuitive Surgical, Regeneron, and Veeva, with amounts well below both the \$15,000 exemption level for a particular matter involving specific parties, and the \$25,000 exemption level for all affected parties based on sector, industry and product. Per review with filer, recent or anticipated HHS duties are not related to any of these recently or currently held spousal assets. Filer advised that she should manage holdings based on guidance provided in her ethics agreement upon joining HHS. Transactions listed on this report executed prior to January 21, were reported beyond the 45-day requirement. No ethics concerns except as noted for assets above.

Transactions

#	DESCRIPTION	TYPE	DATE	NOTIFICATION RECEIVED OVER 30 DAYS AGO	AMOUNT
1	Globant SA- GLOB	Purchase	03/02/2020	No	\$1,001 - \$15,000
2	JP Morgan Chase & Co (JPM)	Purchase	03/02/2020	No	\$1,001 - \$15,000
3	Regeneron Pharmaceuticals Inc (REGN)	Purchase	03/04/2020	No	\$1,001 - \$15,000
4	Delta Air Lines (DAL)	Purchase	03/06/2020	No	\$1,001 - \$15,000
5	JP Morgan Chase & Co (JPM)	Purchase	03/09/2020	No	\$1,001 - \$15,000
6	Boeing Co (BA)	Purchase	03/09/2020	No	\$1,001 - \$15,000

#	DESCRIPTION	TYPE	DATE	NOTIFICATION RECEIVED OVER 30 DAYS AGO	AMOUNT
7	ALTERYX INC- AYX	Purchase	03/10/2020	No	\$1,001 - \$15,000
8	Intuitive Surgical, Inc. - Common Stock (ISRG)	Purchase	03/11/2020	No	\$1,001 - \$15,000
9	Apple Inc. - Common Stock (AAPL)	Purchase	03/12/2020	No	\$1,001 - \$15,000
10	Trade Desk Inc - TTD	Purchase	03/13/2020	No	\$1,001 - \$15,000
11	Dynatrace Holdings - DT	Purchase	03/13/2020	No	\$1,001 - \$15,000
12	Boeing Co (BA)	Purchase	03/18/2020	No	\$1,001 - \$15,000
13	Chevron Corp (CVX)	Purchase	03/18/2020	No	\$1,001 - \$15,000
14	NVIDIA Corporation - Common Stock (NVDA)	Purchase	03/18/2020	No	\$1,001 - \$15,000
15	Crispr - CRSP	Sale	03/02/2020	No	\$1,001 - \$15,000
16	Cardlytics Inc - CDLX	Sale	03/04/2020	No	\$1,001 - \$15,000
17	Cyberark - CYDR	Sale	03/09/2020	No	\$1,001 - \$15,000
18	ALTERYX INC - AYX	Sale	03/09/2020	No	\$1,001 - \$15,000
19	Intuitive Surgical Inc (ISRG)	Sale	03/10/2020	No	\$1,001 - \$15,000
20	CME Group Inc. - Class A Common Stock (CME)	Sale	03/12/2020	No	\$1,001 - \$15,000
21	Dropbox - DBX	Sale	03/12/2020	No	\$1,001 - \$15,000
22	DexCom, Inc. - Common Stock (DXCM)	Sale	03/17/2020	No	\$1,001 - \$15,000
23	Luckin Coffee Inc - LK	Sale	03/27/2020	No	\$1,001 - \$15,000
24	Magnachip - MX	Purchase	02/03/2020	No	\$1,001 - \$15,000
25	Cardlytics Inc - CDLX	Purchase	02/04/2020	No	\$1,001 - \$15,000
26	Tesla Motors, Inc. - Common Stock (TSLA)	Purchase	02/04/2020	No	\$1,001 - \$15,000
27	Collegium Pharmaceutical - COLL	Purchase	02/07/2020	No	\$1,001 - \$15,000

#	DESCRIPTION	TYPE	DATE	NOTIFICATION RECEIVED OVER 30 DAYS AGO	AMOUNT
28	CyberArk Software Ltd. - Ordinary Shares (CYBR)	Purchase	02/10/2020	No	\$1,001 - \$15,000
29	Topbuild Corp - BLD	Purchase	02/14/2020	No	\$1,001 - \$15,000
30	Fortress Transportation - FTAI	Purchase	02/18/2020	No	\$1,001 - \$15,000
31	Dropbox Inc - DBX	Purchase	02/25/2020	No	\$1,001 - \$15,000
32	CME Group Inc. - Class A Common Stock (CME)	Purchase	02/26/2020	No	\$1,001 - \$15,000
33	Tesla Motors, Inc. - Common Stock (TSLA)	Purchase	02/27/2020	No	\$1,001 - \$15,000
34	Paypal Holdings Inc - PYPL	Purchase	02/27/2020	No	\$1,001 - \$15,000
35	NVIDIA Corporation - Common Stock (NVDA)	Purchase	02/28/2020	No	\$1,001 - \$15,000
36	Beyond Meat Inc - BYND	Sale	02/13/2020	No	\$1,001 - \$15,000
37	McDonald's Corp (MCD)	Sale	02/07/2020	No	\$1,001 - \$15,000
38	Magnachip - MX	Sale	02/18/2020	No	\$1,001 - \$15,000
39	Workday Inc - WDAY	Sale	02/25/2020	No	\$1,001 - \$15,000
40	Tesla Motors, Inc. - Common Stock (TSLA)	Sale	02/26/2020	No	\$1,001 - \$15,000
41	Stryker Corp (SYK)	Sale	02/26/2020	No	\$1,001 - \$15,000
42	Arvinas Inc - ARVN	Sale	02/26/2020	No	\$1,001 - \$15,000
43	Crown Castle Intl Corp (CCI)	Sale	02/27/2020	No	\$1,001 - \$15,000
44	Bristol-Myers Squibb (BMY)	Sale	02/27/2020	No	\$1,001 - \$15,000
45	Vertex Pharmaceuticals Incorporated - Common Stock (VRTX)	Sale	02/27/2020	No	\$1,001 - \$15,000
46	Biogen Idec Inc. - Common Stock (BIIB)	Sale	02/28/2020	No	\$1,001 - \$15,000
47	Crispr - CRSP	Purchase	01/02/2020	No	\$1,001 - \$15,000
48	Level3/Harris - LHX	Purchase	01/02/2020	No	\$1,001 - \$15,000

#	DESCRIPTION	TYPE	DATE	NOTIFICATION RECEIVED OVER 30 DAYS AGO	AMOUNT
49	Lockheed Martin (LMT)	Purchase	01/06/2020	No	\$1,001 - \$15,000
50	Vertex Pharmaceuticals Incorporated - Common Stock (VRTX)	Purchase	01/07/2020	No	\$1,001 - \$15,000
51	CyberArk Software Ltd. - Ordinary Shares (CYBR)	Purchase	01/08/2020	No	\$1,001 - \$15,000
52	Arvinas Inc - ARVN	Purchase	01/09/2020	No	\$1,001 - \$15,000
53	Paypal Holdings Inc - PYPL	Purchase	01/13/2020	No	\$1,001 - \$15,000
54	DexCom, Inc. - Common Stock (DXCM)	Purchase	01/13/2020	No	\$1,001 - \$15,000
55	Paypal Holdings Inc - PYPL	Purchase	01/14/2020	No	\$1,001 - \$15,000
56	Bluebird Inc - BLUE	Purchase	01/15/2020	No	\$1,001 - \$15,000
57	Crown Castle Intl Corp (CCI)	Purchase	01/15/2020	No	\$1,001 - \$15,000
58	Virgin Galactic Holdings - SPCE	Purchase	01/15/2020	No	\$1,001 - \$15,000
59	Virgin Galactic Holdings - SPCE	Purchase	01/22/2020	No	\$1,001 - \$15,000
60	NVIDIA Corporation - Common Stock (NVDA)	Purchase	01/30/2020	No	\$1,001 - \$15,000
61	Beyond Meat Inc - BYND	Purchase	01/30/2020	No	\$1,001 - \$15,000
62	NMI Holdings Inc - Common Stock (NMIH)	Sale	01/02/2020	No	\$1,001 - \$15,000
63	Unitedhealth Group Inc (UNH)	Sale	01/02/2020	No	\$1,001 - \$15,000
64	Ubiquiti Inc - UI	Sale	01/07/2020	No	\$1,001 - \$15,000
65	Crispr Inc - CRSP	Sale	01/09/2020	No	\$1,001 - \$15,000
66	Lexinfintech Holdings - LX	Sale	01/13/2020	No	\$1,001 - \$15,000
67	Cosan Limited - CZZ	Sale	01/13/2020	No	\$1,001 - \$15,000
68	Beyond Meat Inc - BYND	Sale	01/15/2020	No	\$1,001 - \$15,000
69	Boeing Co (BA)	Sale	01/15/2020	No	\$1,001 - \$15,000

#	DESCRIPTION	TYPE	DATE	NOTIFICATION RECEIVED OVER 30 DAYS AGO	AMOUNT
70	Dynatrace Holdings - DT	Sale	01/17/2020	No	\$1,001 - \$15,000
71	Luckin Coffee Inc - LK	Sale	01/22/2020	No	\$1,001 - \$15,000
72	Virgin Galactic Holdings - SPCE	Sale	01/29/2020	No	\$1,001 - \$15,000
73	Maxar Technology Inc - MAXR	Sale	01/29/2020	No	\$1,001 - \$15,000
74	Palomar Holdings Inc - PLMR	Sale	01/29/2020	No	\$1,001 - \$15,000
75	Natera Inc - NTRA	Sale	01/30/2020	No	\$1,001 - \$15,000
76	bluebird bio, Inc. - Common Stock (BLUE)	Sale	01/30/2020	No	\$1,001 - \$15,000

Endnotes

Summary of Contents

The 278-T discloses purchases, sales, or exchanges of securities in excess of \$1,000 made on behalf of the filer, the filer's spouse, or dependent child. Transactions are required to be disclosed within 30 days of receiving notification of a transaction but not later than 45 days after the transaction. Filers need not disclose (1) mutual funds and other excepted investment funds; (2) certificates of deposit, savings or checking accounts, and money market accounts; (3) U.S. Treasury bills, notes, and bonds; (4) Thrift Savings Plan accounts; (5) real property; and (6) transactions that are solely by and between the filer, the filer's spouse, and the filer's dependent children.

Privacy Act Statement

Title I of the Ethics in Government Act of 1978, as amended (the Act), 5 U.S.C. app. § 101 et seq., as amended by the Stop Trading on Congressional Knowledge Act of 2012 (Pub. L. 112-105) (STOCK Act), and 5 C.F.R. Part 2634 of the U. S. Office of Government Ethics regulations require the reporting of this information. Failure to provide the requested information may result in separation, disciplinary action, or civil action. The primary use of the information on this report is for review by Government officials to determine compliance with applicable Federal laws and regulations. This report may also be disclosed upon request to any requesting person in accordance with sections 105 and 402(b)(1) of the Act or as otherwise authorized by law. You may inspect applications for public access of your own form upon request. Additional disclosures of the information on this report may be made: (1) to any requesting person, subject to the limitation contained in section 208(d)(1) of title 18, any determination granting an exemption pursuant to sections 208(b)(1) and 208(b)(3) of title 18; (2) to a Federal, State, or local law enforcement agency if the disclosing agency becomes aware of violations or potential violations of law or regulation; (3) to a source when necessary to obtain information relevant to a conflict of interest investigation or determination; (4) to the National Archives and Records Administration or the General Services Administration in records management inspections; (5) to the Office of Management and Budget during legislative coordination on private relief legislation; (6) when the disclosing agency determines that the records are arguably relevant to a proceeding before a court, grand jury, or administrative or adjudicative body, or in a proceeding before an administrative or adjudicative body when the adjudicator determines the records to be relevant

to the proceeding; (7) to reviewing officials in a new office, department or agency when an employee transfers or is detailed from one covered position to another, a public financial disclosure report and any accompanying documents, including statements notifying an employee's supervising ethics office of the commencement of negotiations for future employment or compensation or of an agreement for future employment or compensation; (8) to a Member of Congress or a congressional office in response to an inquiry made on behalf of and at the request of an individual who is the subject of the record; (9) to contractors and other non-Government employees working on a contract, service or assignment for the Federal Government when necessary to accomplish a function related to this system of records; (10) on the OGE Website and to any person, department or agency, any written ethics agreement, including certifications of ethics agreement compliance, filed with OGE by an individual nominated by the President to a position requiring Senate confirmation; (11) on the OGE Website and to any person, department or agency, any certificate of divestiture issued by OGE; (12) on the OGE Website and to any person, department or agency, any waiver of the restrictions contained in Executive Order 13770 or any superseding executive order; (13) to appropriate agencies, entities and persons when there has been a suspected or confirmed breach of the system of records, the agency maintaining the records has determined that there is a risk of harm to individuals, the agency, the Federal Government, or national security, and the disclosure is reasonably necessary to assist in connection with the agency's efforts to respond to the suspected or confirmed breach or to prevent, minimize, or remedy such harm; and (14) to another Federal agency or Federal entity, when the agency maintaining the record determines that information from this system of records is reasonably necessary to assist the recipient agency or entity in responding to a suspected or confirmed breach or in preventing, minimizing, or remedying the risk of harm to individuals, the recipient agency or entity, the Federal Government, or national security. See also the OGE/GOVT-1 executive branch-wide Privacy Act system of records.
